Today: 30 June 2026
Browse Category

NASDAQ:ARQT 30 December 2025 - 12 January 2026

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

New York, January 12, 2026, 15:41 ET — Regular session Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading.
12 January 2026
··
Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates

Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates

NEW YORK, January 1, 2026, 21:21 ET — Market closed With U.S. markets closed for New Year’s Day, shares of Arcutis Biotherapeutics Inc last closed up 3.42% at $29.04 in the final trading session of 2025. The stock ranged from $28.08 to $29.67 on volume of about 1.87 million shares. ARQT is up about 99% over the past year and has traded between $11.13 and $31.77 over the last 52 weeks. Investing.com
2 January 2026
··

Stock Market Today

  • Marzetti (MZTI) Stock Drops 6.8% as Q1 Misses Estimates, Peer Group Lags
    June 29, 2026, 6:07 PM EDT. The Marzetti Company (NASDAQ:MZTI) kept Q1 revenues flat at $451.8 million, coming in 2.6% below where analysts were looking. EPS and EBITDA both fell in the quarter. CEO David A. Ciesinski said gross profit hit a record, pushed up by frozen bread and dinner roll sales, though overall net sales declined thanks to weaker categories and less demand from club stores. Foodservice posted a small sales gain. Marzetti shares dropped 6.8% after the report, closing at $115.92. The broader shelf-stable food group-17 stocks-had mixed Q1s, with average share prices off 3.2% and next-quarter revenue guidance 11.6% lower, pointing to more trouble across the sector.
Go toTop